|
|
|
European Biopharmaceutical Review
|
| Vaccines are a group of products that include some of the oldest biological pharmaceutical entities. They are also an area where new techniques and manufacturing technologies are giving rise to significant growth. While eradication of some historic diseases has led to a lower need for prophylaxis, the resurgent threat of bioterrorism has given impetus to finding new and rapid methods for producing vaccines against a range of new and old threats, such as Anthrax. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
PHASE II & IIa Clinical Trials
21-22 February 2012, Lancaster London Hotel, London
Learn how to overcome challenges in adapting the development process to achieve early Proof of Concept at Informa's 13th Annual Phase I & IIa Clinical Trials event.
More info >> |
|
 |
News and Press Releases |
 |
Norwich Expands Capabilities for Phase I-III Clinical Trials
Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I – III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
More info >> |
|
|
